Open Accessibility Menu
Clinical Trials

Clinical Trials in West Alabama

Through our clinical trials program, patients who qualify can access other health care alternatives and investigational new drugs long before they are available on the open market. The Lewis & Faye Manderson Cancer Center jointly conducts clinical research with MD Anderson Cancer Center.

The Manderson Cancer Center at DCH Regional Medical Center is a National Cancer Institute (NCI) Central Institutional Review Board Signatory Institution. We are also an affiliate member of NRG Oncology which brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

During the months of January through December 2021, a total of 58 patients were accrued to trials, and the following data were collected:

  • Treatment Trials – 4
  • Patient Registries – 54 is a searchable database that provides patients, family members and the public with information about current ongoing clinical research studies.

For any questions or to learn if you qualify for a clinical trial, please contact our Clinical Research Coordinator, Danielle Daniel, by phone at (205) 759-6237 or by email at

Below is a list of clinical trials that are currently offered at Manderson Cancer Center. We have attached the link for each study for ease in finding detailed information regarding these studies.

NRG Oncology

NRG-GU005 - Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
(Principal Investigator – J. Curtis Tucker, MD)

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer. Click here for details.

NRG-CC003 - A Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
(Principal Investigator - J. Curtis Tucker, MD)

This trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer. Click here for details.

MD Anderson Research Studies

Financial Toxicity in Cancer Patients

(Principal Investigator - J. Curtis Tucker, MD)

This study will seek to generate the early data needed to understand the relationship between constructs and measures of patients' coping resources and psychological response and measures of patients' financial toxicity. To collect this early descriptive data, the overall goal of this study is to identify social, behavioral, and knowledge factors associated with financial toxicity outcomes. Identifying these factors will ultimately help elucidate targets for behavioral, psychosocial, and/or educational and coaching interventions. Click here for details.

Lung Cancer Studies

INSIGHT – An Observational Study Assessing the Clinical Effectiveness of Veristrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer
(Principal Investigator – James W. Evans, MD)

The primary purpose of this study is to assess the physician’s clinical practice patterns while using Veristrat in subjects with non-small cell lung cancer whose tumors are epidermal growth factor receptor (EGFR) wild-type or EGFR negative. Learn more about this clinical trial here.